Welcome to our dedicated page for Sera Prognostics news (Ticker: SERA), a resource for investors and traders seeking the latest updates and insights on Sera Prognostics stock.
Sera Prognostics, Inc. (NASDAQ: SERA) is a biotechnology company based in Salt Lake City, Utah, specializing in the development of innovative diagnostic tests for early prediction of preterm birth risk and other pregnancy complications. Sera's mission is to provide pivotal pregnancy information to improve maternal and neonatal health. The company's flagship product, the PreTRM® Test, offers a unique blood-based biomarker test that predicts the individualized risk of spontaneous premature delivery in asymptomatic singleton pregnancies, allowing for proactive clinical interventions.
Sera Prognostics leverages a proprietary platform integrating proteomics and bioinformatics to discover, develop, and commercialize predictive analytic products that address the unmet needs in women's health. The company is committed to enhancing prenatal care and has formed strategic partnerships, including collaboration with the Bill & Melinda Gates Foundation to make its technologies accessible in underserved regions worldwide.
As a private entity supported by a robust investor base, including renowned names like Domain Associates and InterWest Partners, Sera Prognostics has assembled an expert management team and board of directors with substantial experience in clinical development and women's healthcare diagnostics. Recent achievements include the company's addition to the preliminary list of the Russell 3000 and Russell Small-Cap 2000 indexes, reflecting its growing market presence.
Financially, Sera Prognostics reported a significant reduction in operating expenses in recent quarters, aligning its commercial strategy with current market dynamics. The company continues to focus on advancing its product pipeline, including the development of ambient whole blood collection methods to enhance lab efficiency and reduce costs. The overall strategic directives aim at broadening test adoption and improving health outcomes, ultimately reducing the healthcare costs associated with maternal and neonatal complications.
For the latest updates, financial results, and operational highlights, interested parties can access the company's investor relations page and register for upcoming conference calls.
Sera Prognostics, the Pregnancy Company® (Nasdaq: SERA), announced its participation in two upcoming virtual investor conferences: the BTIG MedTech Conference on February 17, 2022, and the Citi 2022 Healthcare Conference on February 24, 2022. CEO Gregory C. Critchfield will provide updates on the company's innovative pregnancy biomarker solutions. Sera's PreTRM® Test offers individualized risk predictions for preterm birth. Notably, 10% of infants are born prematurely in the U.S., incurring healthcare costs of approximately $25 billion annually.
Sera Prognostics Inc. (NASDAQ: SERA) announced a new agreement with MultiPlan to enhance access to its PreTRM® Test, a blood-based biomarker test predicting the risk of preterm birth. This partnership will allow for better medical intervention through MultiPlan's extensive network of over 700 healthcare payers and 1.2 million providers. The PreTRM® Test is crucial for identifying high-risk pregnancies early, enabling personalized care plans. Sera aims to broaden adoption of this test, which is pivotal for improving maternal and neonatal health while reducing healthcare costs.
Sera Prognostics, known as The Pregnancy Company, will be added to the NASDAQ Biotechnology Index effective December 20, 2021. This inclusion underscores Sera's commitment to enhancing maternal and neonatal health through innovative pregnancy biomarker information. The Nasdaq Biotechnology Index tracks securities in the biotech and pharmaceutical sectors, requiring companies to meet stringent criteria such as market capitalization and trading volume. Sera's PreTRM® test provides early risk assessments for preterm birth, which affects over 10% of U.S. births annually.
Sera Prognostics Inc. (NASDAQ: SERA) announced that the Centers for Medicare & Medicaid Services (CMS) has established a Medicare payment rate of $750.00 for the PreTRM® test under the Proprietary Laboratory Analysis code 0247U. This rate will take effect on January 1, 2022, and applies for CY 2022. While this pricing reinforces the test's value, Medicare coverage is not guaranteed. The company aims to negotiate broader insurance coverage to enhance patient access to this innovative test, which predicts the risk of spontaneous preterm birth.
Sera Prognostics (NASDAQ: SERA), focused on maternal and neonatal health, announced the publication of a study funded by the Bill & Melinda Gates Foundation in partnership with AMANHI. This study validates the predictive performance of the IBP4/SHBG biomarker pair for spontaneous preterm birth (sPTB) in low and middle-income regions. Conducted on 10,001 pregnant women in Bangladesh, Pakistan, and Tanzania, results confirm that the biomarkers predict sPTB effectively, enhancing the potential for broader application outside of the U.S.
Sera Prognostics Inc. (NASDAQ: SERA) announced the appointment of Sandra A. J. Lawrence to its Board of Directors. Ms. Lawrence brings extensive leadership experience and insights from her roles in public and private boards, as well as her tenure as CFO at Children’s Mercy Hospital. The company aims to leverage her expertise to enhance maternal and neonatal health and drive long-term revenue growth. Sera Prognostics specializes in innovative pregnancy biomarker solutions, particularly its PreTRM® test, which aims to predict preterm birth risks.
Sera Prognostics Inc. (Nasdaq: SERA) reported a significant revenue increase for Q3 2021, achieving $23,000 compared to $5,000 in Q3 2020. Operating expenses rose to $9.5 million from $4.6 million, primarily due to expanded sales operations and public company costs. R&D spending increased to $2.7 million, reflecting heightened clinical study efforts. The company faced a net loss of $9.9 million, up from $5.1 million year-over-year. Sera continues to see early payer revenues for its PreTRM® test, emphasizing its commitment to improving maternal and neonatal health.
Sera Prognostics, Inc. (NASDAQ: SERA) announced the appointment of Zhenya Lindgardt to its Board of Directors, effective immediately. Lindgardt, with extensive experience in healthcare and technology, aims to enhance the company's mission to improve maternal and neonatal health. Currently the CEO of The Commons Project Foundation, she has also held significant positions at Uber Technologies and The Boston Consulting Group. CEO Gregory C. Critchfield expressed enthusiasm about Lindgardt’s contributions towards innovative solutions for pregnancy-related challenges.
Sera Prognostics (NASDAQ: SERA) has appointed Woodrow Myers, M.D., M.B.A., as an advisor for public and political affairs. Dr. Myers will spearhead initiatives addressing health equity and disparities during pregnancy, a significant focus for the company. Gregory C. Critchfield, CEO, emphasized Dr. Myers' leadership experience in healthcare management and quality initiatives. Sera Prognostics aims to enhance maternal and neonatal health through innovative diagnostic tests like the PreTRM®, which predicts preterm birth risk, thereby enabling timely interventions.
Sera Prognostics (NASDAQ: SERA) announced the publication of a rigorous validation for its PreTRM® test, identifying a clinical decision point at a 15% risk for spontaneous preterm birth (sPTB). The findings, from the PAPR and TREETOP studies involving over 10,000 subjects, indicate that patients at or above this threshold face significantly higher risks, including severe neonatal morbidity. This validation supports the clinical utility of the PreTRM® test in proactive maternal care, potentially improving pregnancy outcomes and reducing healthcare costs.
FAQ
What is the current stock price of Sera Prognostics (SERA)?
What is the market cap of Sera Prognostics (SERA)?
What is Sera Prognostics' main product?
Where is Sera Prognostics headquartered?
What is the mission of Sera Prognostics?
Who are some of the major investors in Sera Prognostics?
What recent financial milestone has Sera Prognostics achieved?
How does the PreTRM® Test work?
What are the benefits of the PreTRM® Test?
What strategic partnerships does Sera Prognostics have?
What are the company's future plans for expanding its product offerings?
What challenges does Sera Prognostics face?
